Search

Displaying results 5241 - 5250 of 8698 in total
  1. Drug

    Navepegritide

    go.drugbank.com/drugs/DB17824
    ApprovedInvestigational

    antagonizes the overactive fibroblast growth factor receptor 3 (FGFR3) signaling pathway responsible for impaired bone growth in individuals with achondroplasia. … [L56065] Navepegritide was approved by the US FDA in February 2026 for use in patients 2 years of age and older with achondroplasia with open epiphyses.[L56058,L56065]

  2. Drug

    AMP-201

    go.drugbank.com/drugs/DB18663
    Experimental

    AMP-201 comprises an adeno-associated virus type 8 vector (AAV8) encoding the collagen Q gene (COLQ). It is under investigation for the treatment of collagen Q congenital myasthenia.

  3. Drug

    DTX-101

    go.drugbank.com/drugs/DB17699
    Investigational

    It was previously investigated for the treatment of hemophilia B; however, the clinical development of DTX-101 was discontinued.[L46103] … DTX-101 is an investigational gene therapy consisting of an adeno-associated virus serotype Rh10 vector encoding the human Factor Ix gene.

  4. Drug

    Clothiapine

    go.drugbank.com/drugs/DB13256
    Approved

    Clothiapine has been approved in European countries and is an atypical antipsychotic, shown to be useful in some treatment-resistant patients.

  5. Drug

    P-113D

    go.drugbank.com/drugs/DB04987
    Experimental

    It is being pursued as a potential treatment for cystic fibrosis by Demegen, Inc. … P-113D is a novel 12 amino-acid antimicrobial peptide drug derived from histatins, which are compounds found naturally in human saliva.

  6. Drug

    Pegpleranib

    go.drugbank.com/drugs/DB06325
    Investigational

  7. Drug

    Tofisopam

    go.drugbank.com/drugs/DB08811
    Investigational

    Although Tofisopam is not approved for sale in North America, it is approved for use in various countries worldwide, including parts of Europe. … The D-enantiomer ([dextofisopam]) is currently in phase II trials in the U.S. for the treatment of irritable bowel syndrome.

    Categories: Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors
  8. Drug

    Dilmapimod

    go.drugbank.com/drugs/DB12140
    Investigational

    Previous p38 MAP-kinase inhibitors have been hindered in development by liver toxicity. Methotrexate (common treatment for RA patients) also has potential liver toxicity.} … Dilmapimod (SB-681323) is a p38 MAP-kinase inhibitor that has potential uses in inflammatory conditions such as RA (Rheumatoid Arthritis).

  9. Drug

    Vespula maculifrons venom protein

    go.drugbank.com/drugs/DB10956
    Approved

    Vespula maculifrons venom protein is an extract of Vespula maculifrons venom. Vespula maculifrons venom protein is used in allergenic testing.

  10. Drug

    Dolichovespula maculata venom protein

    go.drugbank.com/drugs/DB10958
    Approved

    Dolichovespula maculata venom protein is an extract of Dolichovespula maculata venom. Dolichovespula maculata venom protein is used in allergenic testing.